GLP-1 Agonists and Tirzepatide Show Strong Kidney Protection Across Diverse Patients

Chronic Kidney Disease (CKD) is a global health crisis, often progressing from common conditions like Type 2 Diabetes and obesity. These metabolic disorders significantly increase the risk of kidney damage and failure. While GLP-1 receptor agonists and Tirzepatide are known for their efficacy in managing blood sugar and weight, a comprehensive understanding of their renal benefits across different CKD stages and metabolic profiles has been fragmented. This scoping review addresses the critical need for a synthesized overview of how these novel therapies impact kidney health in patients with varying degrees of kidney impairment and metabolic phenotypes.

The review consistently found that both GLP-1 receptor agonists and Tirzepatide conferred significant renal protective effects across a spectrum of CKD stages and metabolic phenotypes. Specifically, studies showed that GLP-1 receptor agonists led to a 30-45% reduction in albuminuria (a marker of kidney damage) compared to placebo or standard care, with benefits observed even in advanced CKD. Tirzepatide, a dual GLP-1/GIP receptor agonist, demonstrated a 20-30% slower decline in estimated glomerular filtration rate (eGFR), a key measure of kidney function, over 2-4 years of treatment. The most impactful finding was the consistent and robust 25-40% lower risk of major adverse kidney events (MAKE), including sustained eGFR decline, end-stage kidney disease, or renal death, across various patient populations treated with these agents. These renal benefits were evident regardless of whether patients presented primarily with Type 2 Diabetes or overweight/obesity, highlighting a broad applicability of these therapies for kidney protection.